UNITED STATES COURT OF APPEALS

Tenth Circuit

Byron White United States Courthouse

1823 Stout Street

Denver, Colorado 80294

(303) 844-3157

Patrick J. Fisher, Jr. Elisabeth A. Shumaker

Clerk Chief Deputy Clerk

June 10, 1997

TO: All recipients of the captioned opinion

RE: 95-1085, 95-1104, 95-1123, Oja v. Howmedica, Inc.

 April 16, 1997

Please be advised of the following correction to the captioned decision:

Due to a formatting error, the section headings are incorrectly labeled. The Arabic

numbers should be Roman numerals.

A corrected version of the opinion is attached for your convenience.

Very truly yours,

Patrick Fisher, Clerk

Susie Tidwell

Deputy Clerk

encl.
F I L E D

United States Court of Appeals

Tenth Circuit

APR 16 1997

PATRICK FISHER

Clerk

PUBLISH

UNITED STATES COURT OF APPEALS

TENTH CIRCUIT

MAUREEN G. OJA,

Plaintiff - Appellee/

Cross - Appellant,

v.

HOWMEDICA, INC., a Delaware

corporation,

Defendant - Appellant/

Cross - Appellee.

--------------------------

PRODUCT LIABILITY ADVISORY

COUNCIL, INC.; HEALTH

INDUSTRY MANUFACTURERS

ASSOCIATION; ASSOCIATION OF

TRIAL LAWYERS OF AMERICA,

Amici Curiae.

No. 95-1085, 95-1104, 95-1123

APPEAL FROM THE UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF COLORADO

(D. Ct. No. 93-C-858)

Malcolm E. Wheeler, Parcel, Mauro, Hultin & Spaanstra, Denver, Colorado,

appearing for Defendant-Appellant/Cross-Appellee.
- 2 -

Elizabeth C. Moran, Pryor, Johnson, Montoya, Carney & Karr, Englewood,

Colorado (Peter W. Pryor, Pryor, Johnson, Montoya, Carney & Karr, Englewood,

Colorado, and Thomas L. Roberts, Roberts & Zboyan, Denver, Colorado, with her

on the briefs), appearing for Plaintiff-Appelle/Cross-Appellant.

Robert N. Weiner and Steve J. Boom, Arnold & Porter, Washington, DC, and

Hugh Young, Jr., Product Liability Advisory Council, Inc., Reston, Virginia, for

amicus curiae Product Liability Advisory Council, Inc.

Bruce N. Kuhlik and Jennifer A. Johnson, Covington & Burling, Washington, DC,

and Donnellda Rice, Health Industry Manufacturers Association, Washington,

DC, for amicus curiae Health Industry Manufacturers Association.

Pamela A. Liapakis, President, Association of Trial Lawyers of America,

Washington, DC and Jeffrey Robert White, Washington, DC, for amicus curiae

Association of Trial Lawyers of America.

Before TACHA, BRISCOE, and MURPHY, Circuit Judges.

TACHA, Circuit Judge.

Maureen Oja brought a products liability action against Howmedica, Inc.,

the manufacturer of a prothestic hip replacement system, asserting three claims

relevant to this appeal: (1) negligence, (2) negligent failure to warn, and (3) strict

liability. At the close of the plaintiff’s case, the district court granted

Howmedica’s motion for a directed verdict on Oja’s strict liability manufacturing

defect claim. The court, however, permitted Oja to proceed with her strict

liability claims based on design and warning defects. 
- 3 -

The jury returned a general verdict for Howmedica on the negligence and

remaining strict liability claims. The jury, however, found for Oja on her

negligent failure to warn claim. The jury awarded Oja $896,921 in compensatory

and $896,921 in punitive damages. The district court reduced the damage award

to $448,460.50 and $612,535.96, respectively, and awarded Oja prejudgment

interest from the date the action accrued.

 On appeal, Howmedica argues that: (1) the Medical Device Amendments

of 1976 (“MDA”) preempts Oja’s negligent failure to warn claim; (2) the jury’s

finding of negligent failure to warn is inconsistent with its verdict for Howmedica

on the strict liability and negligence claims; (3) the district court erred in

submitting both a “negligence” and “negligent failure to warn” claim to the jury

without properly instructing the jury about the elements and burdens of proof on

each claim; and (4) punitive damages cannot be awarded as a matter of law

because the evidence was insufficient to show that Howmedica acted wantonly or

recklessly. 

In her cross-appeal, Oja raises two issues. Oja argues that the district court

erred in (1) dismissing her strict liability claim based on a manufacturing defect

and (2) awarding her prejudgment interest from the date that her action “accrued”

as defined by the relevant statute of limitations rather than the date of her injury. 
- 4 -

We exercise jurisdiction pursuant to 28 U.S.C. § 1291. For the reasons set

forth below, we affirm the district court’s ruling that the MDA does not preempt

Oja’s negligent failure to warn claim. We reverse and remand for a new trial,

however, because we conclude that the jury’s finding of negligent failure to warn

is irreconcilably inconsistent with its verdict for Howmedica on the strict liability

claim. We also reverse the district court’s order granting a directed verdict for

Howmedica on the strict liability manufacturing defect claim. Because we

remand for a new trial, we do not address the remaining issues on appeal.

BACKGROUND

The Porous-Coated Anatomic One-Piece Acetabular Component hip (“PCA

hip”) consists of three components: (1) a metal stem that is inserted into the

central canal of the patient’s large upper leg bone, (2) a cup that is inserted into

the patient’s hip socket, and (3) a rounded metal femoral head that is rigidly

attached to the top of the metal stem and is fitted into the cup. The cup is

composed of an outer metal shell and an inner polyethylene liner. The liner

attaches to the metal shell by an integral staking peg projecting from the back of

the liner through a hole in the metal shell. An “anti-rotation lug” prevents the

liner from rotating in the metal shell. Unless the liner is prevented from rotating,
- 5 -

the liner will wear and shed microscopic debris. Such debris may cause a patient

to suffer from severe bone dissolution or “osteolysis.” 

On July 2, 1984, Oja underwent surgery to replace her existing artificial hip

with a PCA hip. Her orthopedic surgeon, Dr. McElhinney, implanted the PCA hip

without using cement because he had concluded that Oja’s existing bone structure

provided little area for cement fixation.

By early 1992, Oja began experiencing severe pain in her hip in the area of

her PCA hip implant. Dr. Richard Evans, an orthopedic surgeon, recommended

immediate surgery. On July 29, 1992, he removed the PCA hip. The surgery

revealed that the staking peg was missing, that the polyethylene liner had

completely disengaged from the metal cup, and that debris had spread into Oja’s

hip joint. Moreover, osteolysis had left large defects in Oja’s hip, especially in

the area of the hole in the cup. On April 21, 1993, Oja filed this products liability

suit against Howmedica.
- 6 -

DISCUSSION 

I. PREEMPTION OF OJA’S NEGLIGENT FAILURE TO WARN CLAIM

a. Overview of the Medical Device Amendments
1Prior to trial, Howmedica moved for summary judgment, claiming that all of Oja’s

state law claims were preempted by the MDA. The district court denied Howmedica’s

motion and its motion for reconsideration. At the close of the evidence, Howmedica

moved for a directed verdict on all of Oja’s state law claims based on MDA preemption. 

The district court denied the motion.

After the jury returned its verdict, Howmedica renewed its motion for judgment as

a matter of law, arguing only that the MDA preempted Oja’s negligent failure to warn

claim. The district court denied the motion. On appeal, Howmedica again argues only

that the MDA preempts Oja’s negligent failure to warn claim. Thus, we do not address

whether the MDA preempts any of Oja’s other state law claims. See State Farm Fire &

Cas. Co. v. Mhoon, 31 F.3d 979, 984 n.7 (10th Cir. 1994) (holding that the failure to raise

an issue in the opening brief waives the issue).

- 7 -

Howmedica argues that the MDA preempts Oja’s negligent failure to warn

claim.1

 Because Congress’s intent is the “ultimate touchstone” in every

preemption case, see Retail Clerks Int’l Ass’n v. Schermerhorn, 375 U.S. 96, 103

(1963), we begin our preemption analysis by outlining the purposes and statutory

framework of the MDA. 

In 1976, Congress enacted the MDA “to provide for the safety and

effectiveness of medical devices intended for human use.” Pub. L. No. 94-295,

90 Stat. 539, 539 (1976) (preamble). The MDA classifies medical devices into

three categories (classes I, II and III) based on the amount of risk they pose to the

public. Class I devices are subject only to “general controls” because they pose

little threat to public heath and safety. 21 U.S.C. § 360c(a)(1)(A). Class II

devices are subject to special controls because “general controls by themselves

are insufficient to provide reasonable assurance of the safety and effectiveness of
- 8 -

the device.” 21 U.S.C. § 360c(a)(1)(B). Class III devices are subject to the most

stringent MDA controls because they present “a potential unreasonable risk of

illness or injury.” 21 U.S.C. § 360c(a)(1)(C).

The MDA automatically classifies a device as a class III device unless the

device fits within one of three exceptions listed. First, a device placed in

commercial distribution prior to May 28, 1976, avoids class III status through a

grandfathering provision. 21 U.S.C. § 360c(f)(1)(A)(I)(I). Second, a post-1976

device may escape classification as a class III device if the FDA has reclassified

the device as a class I or II device. 21 U.S.C. § 360c(f)(1)(A)(I)(II); 21 U.S.C.

§ 360c(f)(1)(B). Finally, a device may avoid class III device status if it is

“substantially equivalent” to a grandfathered device or a post-1976 device that the

FDA has classified as a class I or II device. 21 U.S.C. § 360c(f)(1)(A)(ii).

Manufacturers intending to market any new medical device must submit a

premarket notification to the FDA. 21 U.S.C. § 360(k). In addition to the

premarket notification (also known as the “§ 510(k) process”), Class III devices

must undergo a comprehensive premarket approval (“PMA”) process before

marketing. 21 U.S.C. § 360e. The purpose of the PMA is to provide the FDA

with “reasonable assurance” that the device is safe and effective. 21 U.S.C. §

360e(d)(2).
- 9 -

While the MDA contemplates that most Class III devices will reach the

market only through the PMA process, a manufacturer may obtain market

approval through any of three alternative processes. First, the MDA contains a

grandfathering provision which allows pre-1976 devices to remain on the market

without FDA approval until the FDA completes the PMA. 21 U.S.C.

§ 360e(b)(1)(A); 21 C.F.R. § 814.1(c)(1). Second, the MDA contains an

investigational device exemption (“IDE”) for new devices under clinical

investigation to determine their safety or effectiveness. See 21 U.S.C. § 360j(g). 

In order to foster the development of useful devices, IDE procedures allow

manufacturers to begin limited marketing of new devices without undergoing the

rigorous PMA process. 21 U.S.C. § 360j(g)(1). Finally, a Class III device may

reach the market without undergoing the PMA procedures if the FDA determines,

on the basis of the § 510 process, that the device is “substantially equivalent” to a

device already on the market. 21 U.S.C. § 360e(b)(1)(B).

 b. Regulation of the PCA Hip Under the MDA

On April 25, 1983, Howmedica filed a premarket notification submission

with the FDA, seeking permission to market the PCA hip under the § 510(k)

process. The application included sample labels, a description of the intended

use, a description of the product (dimensions, materials, processing, and

sterilization procedures), photographs of the components, engineering drawings,
2Oja underwent her PCA hip surgery on July 2, 1984, when Howmedica’s IDE

application was pending. Thus, at the time of Oja’s surgery, Howmedica had not yet

received an IDE for cementless use. This distinguishes our case from Martin v.

Telectronics Pacing Sys., Inc., 105 F.3d 1090 (6th Cir. 1997) and Becker v. Richards

Med. Co., 937 F. Supp. 181 (N.D.N.Y. 1996).

- 10 -

and a description of test results. During the next few months, the FDA requested

that Howmedica submit additional testing information and certification that the

PCA hip would be used only with cement. Howmedica complied with each of

these requests.

On August 10, 1983, the FDA granted Howmedica permission to market the

PCA hip for use with bone cement pursuant to the § 510(k) process “subject to the

general controls provision of the Federal Food, Drug & Cosmetic Act.” The FDA

also imposed several specific limitations on Howmedica: (1) the PCA hip could

not be labeled or promoted for non-cemented use, (2) the PCA hip could only be

used with low-viscosity cement, and (3) fixation of the PCA hip without cement

would be considered an investigational procedure requiring an IDE. 

On October 18, 1983, Howmedica submitted an IDE application in order to

conduct a clinical study of the PCA hip when used without cement.2 Over the

course of the next year, Howmedica submitted animal studies, comparative

control groups, and other information to the FDA. On December 12, 1984, the

FDA authorized Howmedica to conduct the clinical investigation. After that date,
- 11 -

the PCA could be used without cement in an experimental context, with a

patient’s full informed consent.

On September 4, 1987, the FDA issued its final rule classifying the PCA

hip as a class II medical device when used with cement. 52 Fed. Reg. 33686,

33707 (codified at 21 C.F.R. § 888.350). At that time, the FDA had determined

that classification as a class III device was “not necessary to provide reasonable

assurance of the safety and effectiveness of the device.” 21 C.F.R. § 860.93. 

On October 26, 1989, following the clinical investigation of the PCA hip,

Howmedica filed a request for a PMA to market the PCA hip when used without

cement. The FDA issued a conditional approval letter on April 2, 1991. The

FDA conditioned final approval upon: (1) deleting one word from the proposed

labeling, (2) providing an update of the clinical database, and (3) complying with

future requirements, such as the summation of long-term survivorship data.

In 1991, the FDA inspected and cited Howmedica for several regulatory

violations, including the failure to report information that the PCA hip had caused

serious injury in patients. In response, Howmedica informed the FDA that it

would “voluntarily” issue a “Dear Doctor” letter to surgeons using the device,

instructing them on the proper surgical techniques to avoid damage to the

polyethylene liner of the cup. The FDA indicated that it had “no adverse

comments” about the content of the letter. 
3

In a five to four decision, the Court held that the MDA did not preempt any of the

plaintiffs’ common law claims. Justice Stevens authored the plurality opinion, which

Justices Kennedy, Souter, and Ginsburg joined in its entirety. Justice Breyer, who

concurred in the judgment, joined in Parts I, II, III, V, and VII of the plurality opinion. 

Thus, only those five sections constitute the opinion of the Court.

- 12 -

On February 21, 1992, the FDA reclassified the PCA hip when used

without cement from a class III device to a class II device. See 58 Fed. Reg. 3227

(Jan. 8, 1993). Howmedica therefore invoked the § 510(k) process (rather than

the more rigorous PMA) to obtain authorization to market the PCA hip without

cement. On June 10, 1992, the FDA granted Howmedica permission to market the

PCA hip when used without cement under the premarket notification procedure. 

On January 8, 1993, the FDA published its final rule classifying the PCA hip as a

class II medical device when used without cement. 58 Fed. Reg. 3227, 3228

(codified at 21 C.F.R. § 888.358) 

c. MDA Preemption Analysis in Medtronic, Inc. v. Lohr

 In Medtronic, Inc. v. Lohr, 116 S. Ct. 2240 (1996), the Supreme Court

addressed whether the MDA’s general labeling regulations preempted a state law

negligent failure to warn claim for injuries suffered by the recipient of a

pacemaker, a class III device.3

 Id. at 2256-58. The regulations require

manufacturers of every medical device, with a few limited exceptions, to label the

device with “information for use, . . . any relevant hazards, contraindications, side

effects, and precautions.” 21 C.F.R. § 801.109(c). 
- 13 -

The Court began its preemption analysis by looking to the text of the

MDA’s preemption provision (21 U.S.C. § 360k) and the FDA’s regulation

interpreting that provision (21 C.F.R. § 808.1(d)):

§ 360k State and local requirements respecting devices

(a) General Rule

Except as provided in subsection (b) of this section, no State or

political subdivision of a State may establish or continue in effect

with respect to a device intended for human use any requirement-- 

(1) which is different from, or in addition to, any requirement

applicable under this chapter to the device, and

(2) which relates to the safety or effectiveness of the device or to any

other matter included in a requirement applicable to the device under

this chapter.

§ 808.1 Scope

(d) State or local requirements are preempted only when the Food

and Drug Administration has established specific counterpart

regulations or there are other specific requirements applicable to a

particular device under the Act, thereby making any existing

divergent state or local requirements applicable to the device

different from or in addition to, the specific Food and Drug

Administration requirements.

Medtronic, 116 S. Ct. at 2256-58. The Court concluded that the statute and

regulation evinced “an overarching concern that pre-emption occurs only where a

particular state requirement threatens to interfere with a particular federal

interest.” Id. at 2257. 

Based on the MDA’s statutory language and the FDA’s regulation, the

Court developed a two-prong inquiry to determine the preemptive scope of the

MDA. Id. First, a federal requirement must be “applicable to the device” in
4Prior to the Supreme Court’s decision in Medtronic, Howmedica argued that

several FDA “requirements” would preempt Oja’s negligent failure to warn claim. The

Supreme Court rejected most of these grounds in Medtronic. Accordingly, in

- 14 -

question. Id. at 2257 (quoting 21 U.S.C. § 360k). In other words, a federal

requirement will preempt state law only if “specific” to a “particular device.” Id.

(quoting 21 C.F.R. § 808.1(d)). Second, a state requirement must be “with

respect to” a medical device and must be “different from, or in addition to” a

federal requirement. Id. (quoting 21 U.S.C. § 360k). Accordingly, “[s]tate

regulations of ‘general applicability’ are not preempted except where they have

‘the effect of establishing a substantive requirement of a specific device.’” Id.

(quoting 21 C.F.R. § 808.1(d)(1)). 

Applying the two-prong test, the Court concluded that the MDA’s labeling

regulations did not preempt the plaintiffs’ negligent failure to warn claim. First,

the Court found no preemption because the federal labeling regulations reflected

“important but entirely generic concerns about device regulation generally.” Id.

at 2558. Second, the Court concluded that the negligent failure to warn claim

also escaped preemption because its “generality leaves [it] outside the category of

requirements that § 360k envisioned to be ‘with respect to’ specific devices.” Id.

d. Application of Medtronic

In its supplemental brief, Howmedica argues that the FDA imposed two

warning requirements sufficient to preempt Oja’s negligent failure to warn claim.4
Howmedica’s supplemental brief filed after Medtronic, Howmedica limited its

preemption argument to the only viable grounds remaining, namely the FDA’s dealings

with Howmedica in 1983 and 1991. Thus, we address only these grounds.

- 15 -

Howmedica points to the FDA’s regulation of the PCA hip in 1983 and in 1991. 

With respect to Howmedica’s dealings with the FDA in 1983, Howmedica alleges: 

In 1983, when first deciding whether to allow Howmedica to begin

marketing the PCA hip, the FDA four times required Howmedica to

submit more testing, information, and certifications . . . and then

required Howmedica to add, to all labeling and promotional materials

for that specific device, specific warning statements that the device

be used only with bone cement, not cementless . . . . The warnings

specifically required by the FDA did not include any of the warnings

that Oja asked the jury to impose under Colorado tort law.

 

Applt. Supp. Brief at 4 (citations omitted). 

Under the Medtronic two-pronged preemption test, we must first determine

whether the FDA imposed any specific federal warning requirement applicable to

the PCA hip in its 1983 dealings with Howmedica. The record indicates that the

FDA imposed only one labeling requirement on Howmedica: the FDA stated that

Howmedica could not label or promote the PCA hip for non-cemented use. This

mandate constitutes a specific federal requirement applicable to the PCA hip, but

that does not end our preemption inquiry. Like the failure to warn claim at issue

in Medtronic, the general state common law requirements imposed by Oja’s

negligent failure to warn claim were not specifically developed “with respect to”

medical devices. Medtronic, 116. S. Ct. at 2258. Instead, Oja’s negligent failure
- 16 -

to warn claim is predicated upon a general duty applicable to every manufacturer

“to inform users and purchasers of potentially dangerous items of the risks

involved in their use.” Id. Moreover, Howmedica’s general duty to warn users of

potential dangers in this case does not have “the effect of establishing a

substantive requirement for a specific device.” Id. at 2257. Thus, the standard of

care governing Oja’s negligent failure to warn claim is not the type of devicespecific requirement that would threaten the MDA’s federal interests. See id. at

2258. Accordingly, we find no preemption based on Howmedica’s dealings with

the FDA in 1983. 

Similarly, we find no preemption based on the FDA’s regulation of the

PCA hip in 1991. Howmedica alleges:

In 1991 the FDA specifically scrutinized Howmedica’s internal

documents regarding reported problems with the PCA hip,

reexamined Howmedica’s medical device reports pertaining to the

PCA hip (including reports relied on by Oja at trial as evidence of

the need for additional warnings), reexamined Howmedica’s labeling

and warning materials, and imposed device-specific requirements for

specific additional labeling and warnings. The warnings required by

the FDA did not include any of the warnings that Oja asked the jury

to require under Colorado tort law. . . .

Applt. Supp. Brief at 3-4 (citations omitted). First, we note that any FDA

requirement imposed in 1991 would have no preemptive effect as to Howmedica’s

pre-1991 post-sale duty to warn. Second, the record is not clear that the 1991

“voluntary” Dear Doctor letter even constituted an MDA “requirement” at all. 
- 17 -

We need not resolve this question, however, because assuming arguendo that the

warnings contained in the letter were specific federal requirements, we find no

preemption under the second prong of the analysis employed in Medtronic. As

with the 1983 claims, the duties imposed by Oja’s negligent failure to warn claim

do not constitute positive enactments of state law sufficient to constitute a state

requirement developed “with respect to” a medical device. The Court in

Medtronic made clear that the general duty to warn of foreseeable dangers is “not

the kind[] of requirement[] that Congress and the FDA feared would impede the

ability of federal regulators to implement and enforce specific federal

requirements.” Medtronic, 116 S. Ct. at 2258. Accordingly, we affirm the

district court’s ruling that the MDA does not preempt Oja’s negligent failure to

warn claim. 

II. INCONSISTENT JURY VERDICTS 

a. Waiver

Howmedica next contends that we should vacate the judgment entered on

the jury verdict in favor of Oja on her negligent failure to warn claim because it is

irreconcilably inconsistent with the jury verdict in favor of Howmedica on Oja’s

strict liability claims. As a preliminary matter, we must determine whether we

may review this issue. A party’s failure to object to a general jury verdict on the

ground of inconsistency before the jury is discharged constitutes waiver, unless
- 18 -

the verdict is inconsistent on its face such that entry of judgment upon the verdict

is plain error. Hinds v. General Motors Corp., 988 F.2d 1039, 1047 (10th Cir.

1993) (citing Diamond Shamrock Corp. v. Zinke & Trumbo, Ltd., 791 F.2d 1416,

1424 (10th Cir. 1986)).

In this case, the parties do not dispute that the verdict forms required the

jury to return a general verdict. The jury reached a verdict at 5:00 pm on the

night before Thanksgiving. The court then read the verdict, polled the jury,

entered judgment, and excused the jurors. Howmedica relies on Jarvis v.

Commercial Union Assurance Cos., 823 F.2d 392, 393 (10th Cir. 1987), to

support its position that under these circumstances, Howmedica had no

“meaningful opportunity” to object to the verdict and therefore its failure to

object should not constitute waiver. In Jarvis, the jury returned a verdict and

special interrogatory answers that the trial judge recognized as arguably

inconsistent. Id. at 394. In open court, the judge asked the jury to review its

verdict and answers to determine if the jury marked the forms as intended. Id.

After further deliberations, the jury sent the judge a note stating that the forms

were correctly marked and that “if there is a conflict with the Special

Interrogatory form and the Verdict Forms, we will need a description of this

conflict.” Id. at 395. The court informed the parties of the jury’s note and

explained:
- 19 -

I wanted to inquire if there was an inconsistency in the jury’s mind. 

They are saying that there is none, so I am going to bring them in and

publish the verdict.

Id. at 394. Accordingly, the judge read the verdict, polled the jury, entered

judgment, and discharged the jury. Id. We held that “it would be a perverse

default of justice to say that under the circumstances present here, counsel had

waived the right to correct an onerous inconsistency in the jury’s resolution of his

client’s case only because he did not raise an objection.” Id. at 396. 

We find Howmedica’s reliance on Jarvis misplaced. In Jarvis, “the court

summarily declared the conflict resolved and proceeded with entry of the verdict.” 

Id. Under such circumstances, an objection to the verdict as inconsistent would

have been frivolous in light of the trial court’s disposition of the issue. In

contrast to Jarvis, the trial court in this case did not raise and decide the issue sua

sponte before discharging the jury. Instead, the record indicates that Howmedica

had the opportunity to object to any inconsistencies in the verdict prior to the

jury’s discharge or immediately thereafter. In fact, Howmedica’s counsel

objected to at least one aspect of the verdict before leaving the courtroom. The

attorney stated: “I think there are some problems with the verdict in that there are

-- seems to me the punitive damages are above the compensatory.” Howmedica

could have made similar objection to the verdict being inconsistent or complained

that the trial court discharged the jury before Howmedica could make such an
- 20 -

objection. Howmedica did not do this. Under such circumstances, we hold that

Howmedica has waived its right to object to the verdict unless it is “inconsistent

on its face such that entry of judgment upon the verdict is plain error.” Hinds,

988 F.2d at 1047. 

b. Facial Inconsistency

“A verdict that resolves separate and distinct causes of action in favor of

both parties is not inconsistent on its face.” Harris Mkt. Research v. Marshall 

Mktg. & Communications, Inc., 948 F.2d 1518, 1522 (10th Cir. 1991). In

contrast, when “several causes of action are identical and defended on the same

ground, a verdict for the plaintiff on one cause of action and for the defendant on

another is inconsistent.” Diamond Shamrock Corp., 791 F.2d at 1425.

To determine whether the verdicts in this case are irreconcilably

inconsistent, we must examine the relationship between strict liability and

negligence under Colorado law. In Fibreboard Corp. v. Fenton, 845 P.2d 1168,

1174 (Colo. 1993) (en banc), the Supreme Court of Colorado stated: 

Under a negligence theory a plaintiff is required to prove that a

manufacturer’s failure to warn of a risk fell below an acceptable

standard of care. Under a strict liability theory, however, the focus

of the inquiry is whether the defendant failed to warn of particular

risks that were known or knowable in light of the generally 

recognized and prevailing scientific and technical knowledge

available at the time of manufacture and distribution.
- 21 -

Despite the theoretical differences noted in Fibreboard Corp., we have recognized

that Colorado has not drawn a “rigid distinction between negligence and strict

liability failure to warn concepts.” Romero v. International Harvester Co., 979

F.2d 1444, 1452 (10th Cir. 1992). For example, as with all tort claims, the

plaintiff must prove the elements of causation and damages. More importantly,

“[o]ne critical area of overlap is that, ‘[r]egardless of whether a product liability

action is grounded in negligence or strict liability, a plaintiff must prove that the

product was defective.’” Perlmutter v. United States Gypsum Co., 54 F.3d 659,

663 (10th Cir. 1995) (quoting Mile High Concrete, Inc. v. Matz, 842 P.2d 198,

205 (Colo. 1992)). Under either theory, the product must have been defective at

the time of sale. See Perlmutter v. United States Gypsum Co., 4 F.3d 864, 869

(10th Cir. 1993) (holding that in a negligence claim, there is “no post-sale duty to

warn or remedy when the product was non-defective under standards existing at

the time of manufacture”); Fibreboard Corp., 845 P.2d at 1175 (stating that “[i]n

[strict liability] failure-to-warn cases, a product is not defective and unreasonably

dangerous if a particular risk is not known or knowable in light of the generally

recognized and prevailing scientific and technical knowledge available at the time

of manufacture and distribution”). 

In this case, the elements of defectiveness and causation were common to

all of Oja’s claims. The record on appeal reveals that these two elements were
5The jury instruction regarding Oja’s negligent failure to warn claim stated:

If a product manufacturer knows, or in the exercise of reasonable

care should know, that use of the product may be harmful or injurious to a

user, and such risk of harm or injury is not obvious to a reasonable surgeon,

then the manufacturer must use reasonable care to warn the surgeon of the

risk of harm or injury if, and to the extent, and in the manner, a reasonably

careful person would warn under the same or similar circumstances. 

The duty to warn may extend beyond the time of sale of a product

where a danger concerning the product becomes known to the manufacturer

subsequent to the sale and delivery of the product, even though it was not

known at the time of the sale. A manufacturer has no duty to warn surgeons

regarding its product after the product is sold unless you find that the

product was defective and unreasonably dangerous as originally designed

and sold. Where dangerous defects in design come to the manufacturer’s

attention after the device has been sold, the manufacturer has a duty to

either remedy such defects, or, if such a complete remedy is not feasible, to

give physicians adequate warnings and instructions concerning methods for

minimizing danger and injury. Failure to do so is negligence. 

A manufacturer has no duty to warn surgeons using a product about

a newly developed safety device if the product was not defective under

standards existing at the time the product was manufactured. 

Whether or not the PCA hip was defective as originally sold should

be determined by the standard set forth in these instructions of the

plaintiff’s claim for sale of a defective product. 

Here, too, if the defendant had a duty to warn, it would be a duty to

warn members of the medical profession, including the plaintiff’s surgeons.

- 22 -

essentially the only elements disputed at trial. To find for Oja on her negligent

failure to warn claim, the jury had to find that the PCA hip was defective at the

time of sale and caused her injuries.5 To find for Howmedica on Oja’s strict

liability claim, the jury had to find that the PCA hip was either not defective at
6With respect to the strict liability for failure to warn claim, the jury instructions

stated in relevant part: 

 

For the plaintiff, Ms. Oja, to recover from the defendant, Howmedica, on

her claim for sale of a defective product, you must find that all of the

following facts have been proved by a preponderance of the evidence:

(1) The PCA hip was defective and, because of one or more defects, it was

unreasonably dangerous to a person who might reasonably be expected to

use it or be affected by it; 

(2) The PCA hip was defective at the time it was sold by the defendant or

left its control;

(3) Plaintiff incurred injuries, damages or losses; and

(4) The defect in the PCA hip was a cause of the plaintiff’s injuries,

damages or losses.

- 23 -

the time of sale or did not cause her injuries.6 Given these parameters, we hold

that the verdict for Oja on her negligent failure to warn claim and the verdict for

Howmedica on Oja’s strict liability failure to warn claim were facially

inconsistent. Accordingly, we vacate the judgment of the district court and order

a new trial. 

III. DIRECTED VERDICT ON THE MANUFACTURING DEFECT CLAIM

In her cross-appeal, Oja argues that the district court erred in directing a

verdict for Howmedica on Oja’s manufacturing defect claim. The district court

concluded that Oja had failed to present any evidence to support a jury finding

that the PCA hip contained a manufacturing defect. Instead, the court found that

Oja had presented evidence sufficient only to permit a jury to find that the PCA

hip suffered from a design defect.
- 24 -

We review the district court’s grant of a directed verdict de novo, applying

the same standard used by the district court. Knight v. Snap-on Tools Corp., 3

F.3d 1398, 1401 (10th Cir. 1993). “A directed verdict is appropriate only if the

evidence, viewed in the light most favorable to the nonmoving party, ‘points but

one way and is susceptible to no reasonable inferences supporting’ the nonmoving

party.” Id. (internal citations omitted). “However, a mere scintilla of evidence is

insufficient to create a jury question.” Honce v. Vigil, 1 F.3d 1085, 1088 (10th

Cir. 1993). Although federal law dictates whether a directed verdict is

appropriate, in a diversity action we examine the evidence in terms of the

underlying burden of proof as dictated by state law. Mason v. Texaco, Inc., 948

F.2d 1546, 1554 (10th Cir. 1991).

In Hiigel v. General Motors Corp., 544 P.2d 983, 988 (Colo. 1975), the

Supreme Court of Colorado expressly adopted the doctrine of strict liability in

tort for selling a product in a “defective condition unreasonably dangerous to the

user or consumer” as stated in section 402A of the Restatement (Second) of Torts. 

To avoid a directed verdict in a strict liability action brought under Colorado law,

a plaintiff must offer proof of each element set forth in section 402A sufficient to

create an issue of fact. Belle Bonfils Mem’l Blood Bank v. Hansen, 665 P.2d

118, 125 n.12 (Colo. 1983). In particular, a plaintiff must offer sufficient

evidence that the product at issue was in a “defective condition unreasonably
- 25 -

dangerous” at the time the product was sold to the plaintiff. White v. Caterpillar,

Inc., 867 P.2d 100, 104-05 (Colo. Ct. App. 1993). A claim of defect can be

premised on a manufacturing, design, or warning defect. Id. at 105. “The

question in manufacturing defect cases is whether the product as produced

conformed with the manufacturer’s specifications.” Camacho v. Honda Motor

Co., 741 P.2d 1240,1247 (Colo. 1987). A defect in manufacturing usually occurs

because of insufficient quality control. See, e.g., LEWIS BASS, PRODUCTS

LIABILITY: DESIGN AND MANUFACTURING DEFECTS, § 4.07, at 57 (1986).

Under Colorado law, a plaintiff may prove a manufacturing defect by direct

or circumstantial evidence. See Union Ins. Co. v. RCA Corp., 724 P.2d 80, 82-83

(Colo. Ct. App. 1986). In this case, the staking peg was completely missing when

Dr. Evans removed Oja’s PCA hip. Under such conditions, direct proof of a

defect in the staking peg was impossible. See id. at 83. Accordingly, Oja relied

exclusively on circumstantial evidence to support her manufacturing defect claim.

 Oja’s surgeon testified that he made only a visual check for improper

staking before implanting the PCA hip. Her expert concluded that although the

surgeon saw no noticeable defect in the device, the PCA hip could still have

suffered from an internal manufacturing defect in the staking peg. To support her

claim, Oja introduced evidence that Howmedica received at least two product

experience reports (“PERs”) describing instances in which surgeons discovered a
- 26 -

staking problem only after implanting the PCA hip and performing a trial

reduction. 

In addition to those two PERs, Oja submitted six other PERs describing

inadequate staking in PCA hips manufactured near the time Howmedica

manufactured Oja’s PCA hip. In particular, Howmedica received a PER on

February 1, 1984, that stated: 

Nature of Complaint [By Surgeon]: Please replace to my stock--

no charge--while dislocating the hip during a trial reduction in

surgery the plastic core came out of metal backing.

Results of Evaluation [By Howmedica Employee]: The assembly

staking on above part was inadequate. We have established a push

test & careful visual inspection (100%) on PCA acetabular cup

assemblies which should preclude such failures. 

Similarly, Howmedica received a PER on August 27, 1984, that stated:

Nature of Complaint [By Surgeon]: Customer complains that the

HDP is not close enough in the metal part.

Results of Evaluation [By Howmedica Employee]: As received the

fit of the insert to the cup was excellent but the stake holding the

components together was poor. This part was of very early

production (Oct. 1983) and the staking process still required

improvement. The process has been improved and we have also

added a “push test” to the stake to assure adequate assembly.

Finally, Oja submitted evidence indicating that Howmedica rejected one of

the PCA hips from the same lot as Oja’s PCA hip because of a staking problem. 

The remaining devices in her lot underwent a “tightness of plastic insert to cup

VISUAL” test. Howmedica did not, however, conduct any other performance
- 27 -

tests on the lot of PCA hips containing her hip. Oja claims the absence of

adequate inspection and testing procedures increased the likelihood that her PCA

hip suffered from a manufacturing defect.

We have carefully reviewed the record and conclude that Oja presented

sufficient evidence from which a jury could reasonably conclude that Oja’s PCA

hip suffered from a manufacturing defect. The staking peg in Oja’s PCA hip was

completely missing. Within a year of the device’s manufacture, Howmedica sent

a number of other PCA hips to surgeons that did not “conform to [Howmedica’s]

specifications” because of inadequate staking. See Camacho, 741 P.2d at 1247. 

The PERs strongly suggest that problems with inadequate staking were not

infrequent during early production of the PCA hip. More importantly, the PERs

indicate that the problems could have been caused by inadequate testing and

inspection in the manufacturing process, in addition to inadequate design. Under

such circumstances, we hold that a jury could reasonably conclude that Oja’s PCA

hip suffered from a manufacturing defect.

CONCLUSION

We AFFIRM the district court’s order finding that the MDA does not

preempt Oja’s negligent failure to warn claim. We VACATE the judgment

entered on the jury’s verdict and REMAND for a new trial because we hold that
- 28 -

the jury’s verdict for Howmedica on the strict liability failure to warn claim but

against Howmedica on the negligent failure to warn claim are irreconcilably

inconsistent. We also REVERSE the directed verdict for Howmedica on Oja’s

strict liability manufacturing defect claim. Because we remand for a new trial, we

do not address the remaining issues presented on appeal.